Pfizer has begun a Phase 2 and 3 clinical trial of its Covid-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release.

KIFI

Idaho Falls

Bonneville County

Idaho

United States

Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17 - Local News 8

Pfizer announced Wednesday it is launching a clinical trial to study the effectiveness of its COVID-19 antiviral pill in young children.


Ad Fontes Media

All Sides

Media Bias/Fact Check

abc News

The Walt Disney Company

Pfizer launches clinical trial testing its COVID-19 pill in children aged 6 and older

Pfizer has begun a Phase 2 and 3 clinical trial of its Covid-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release.  

Warner Bros. Discovery

Atlanta

Fulton County

Georgia

Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17

(CNN) — Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release.The study will evaluate the safety and efficacy of the treatment in children who have COVID-19 symptoms and a confirmed infection, who are not hospitalized and who are at risk of severe disease.Paxlovid is already authorized by the US Food and Drug Administration for high-ri…

CBS Local

National Amusements

Michael Redstone

Pfizer Begins Phase 2 And 3 Trial Of COVID-19 Antiviral Paxlovid In Children Ages 6 To 17

By Amanda Sealy, CNNPfizer has begun a Phase 2 and 3 clinical trial of its Covid-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release.The study will evaluate the safety and efficacy of the treatment in children who have Covid-19 symptoms and a confirmed infection, who are not hospitalized and who are at risk of severe disease.Paxlovid is already authorized by the US Food and Drug Administration…

News-Press & Gazette Company

By Amanda Sealy, CNN Pfizer has begun a Phase 2 and 3 clinical trial of its Covid-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will evaluate the safety and efficacy of the treatment in children who have Covid-19 symptoms and a confirmed infection,

KRDO

Colorado Springs

El Paso County

Colorado

Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17 - KRDO

CNBC's Meg Tirrell joins 'Squawk Box' to report that Pfizer has started a trial of its Covid-19 antiviral treatment, known as Paxlovid, in kids aged 6 and older.

CNBC

Roberts family

Pfizer begins trial of Covid antiviral pill in kids

Melissa Velásquez Loaiza (CNN) — Pfizer has begun a phase 2 and 3 clinical trial of its antiviral treatment against covid-19, Paxlovid, in children ages 6 to 17, the company said Wednesday in a statement. The study will evaluate the safety and efficacy of treatment in children who have symptoms of COVID-19 and a confirmed infection, who are not hospitalized, and who are at risk of severe illness. Paxlovid is already approved by the US Food and D…

KVIA

Panama City

Bay County

Florida

Pfizer begins phase 2 and 3 trial of the pill against covid-19 Paxlovid in children aged 6 to 17 years

Pfizer on Wednesday announced it has begun phase 2 and 3 stages of its study into the use of its antiviral COVID-19 treatment in young children.

The Hill

Nexstar Media Group

Washington

District of Columbia

Pfizer begins stage 2 and 3 trials of COVID-19 antiviral treatment on children

Pfizer said on Wednesday it has begun a mid-to-late-stage study of its antiviral COVID-19 pill for non-hospitalized children aged 6-17 years who are at high…

Financial Post

Leon Cooperman

Allianz

Canada

Pfizer begins COVID pill study in high-risk children aged 6-17

Pfizer announced this morning that it has initiated the next phase of a clinical trial to evaluate the safety and efficacy of its COVID-19 antiviral pill, Paxlovid, in children ages 6 to 17.

News12

Altice USA

New York

Pfizer begins next phase of trial to study safety of its COVID-19 antiviral pill in children

Europe

Vaccinations

Pfizer

Vaccines

Coronavirus

Medical

Pandemic

Frankfurt

New York City

Hesse

Germany

Bloomberg

NBC News

abc 6 Philadelphia

abc 7 Chicago

abc 7 LA

abc 7 NY

Medical Xpress

abc11 Raleigh

FijiTimes

abc30 News

Forbes

MarketWatch

WHDH

Politico

Wall Street Journal

Seeking Alpha

KITV4 News

KCRG

Denver 7 News

Business Recorder

WBAL

KION

Barron's

Regina Leader-Post

Western Mass News

Black Chronicle

CNN Chile

Live5News

WAVE

WKYT

CBS58

KOTA

WSMV Nashville

Good Morning America

wctv.tv

WSFA 12 News

K8 News

WREX

Metro

صوت بيروت إنترناشونال

WAOW

RTTNews

pfizer.com

Paxlovid is currently authorized under U.S. Food and Drug Administration emergency use authorization in both high-risk adult and high- risk pediatric patients 12 years of age and older weighing at least 40 kg. Pfizer said it is working to develop an age-appropriate formulation for three additional planned cohorts of younger than 6 years old.

Pfizer begins Phase 2 and 3 trial of Covid-19 antiviral Paxlovid in children ages 6 to 17

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics